Call Girl In Zirakpur ❤️♀️@ 9988299661 Zirakpur Call Girls Near Me ❤️♀️@ Sexy...
SPARK in the Valley of Death, Heikki Joensuu, Helsinki University Hospital.
1. SPARK in the Valley of Death
Heikki Joensuu
Comprehensive Cancer Center Helsinki, Helsinki University Hospital,
and University of Helsinki
2. • 90 Nobel laureates
• Endowments 7.7 billion € in 2014
University of
Cambridge
Charles Darwin Stephen Hawkins Isaac Newton
3. Stanford faculty and alumni:
• Founded companies including Google, Hewlett-Packard,
Nike, Sun Microsystems, Instagram and Yahoo!
• The companies founded generate >$2.7 trillion in annual
revenue, equivalent to the 10th-largest economy in the
world
• 30 living billionaires
• 17 astronauts
• 60 Nobel Prize laureates
Stanford
University
4. Can we one day have a similar world-class
top university in Finland?
We would need
• The top people
• The top research
• Good funding and resources
…and these may be linked
5. Creating a positive cycle for financing
• Developing of inventions to products locally, new companies
• Collaboration and partnership with industry
• Meeting forums for academic investigators and investors
6. An example: A new drug for a
relatively rare type of cancer
(GIST)
7. Gastrointestinal stromal tumour (GIST)
• May be the most common type of soft tissue sarcoma
• Incidence about 10 cases/million/year
• Variable malignancy potential
• Some GISTs are virtually benign, others are aggressive
cancers
• Risk stratification schemes therefore needed
• Local GISTs are treated with surgery
• Imatinib (a targeted drug for GIST and one type of
leukemia) is given after surgery for 3 years when the
risk of recurrence is considered high
Imatinib annual sales in 2015: 4.65 billion dollars
8. Treatment of advanced GIST
• The first-line treatment has been imatinib since 20021,2
• Most GISTs eventually develop acquired drug resistance (appr. 80%
within 10 years)
• The approved second-line agent (sunitinib) and third-line agent
(regorafenib) have only moderate efficacy with the time to
progression about 6 months
• Novel agents needed!
1Joensuu et al. NEJM 2001; 2Demetri et al. NEJM 2002
9. 0
20
40
60
80
100
Alivewithoutrecurrence(%)
0 2 4 6 8 10 12 14
Time since imatinib initiation
Years
Successive GIST patients with metastatic disease treated in
Helsinki since the year 2000
Median time to progression 3.0 years
Median overall survival 6 years
Appr. 25% survive for 10 years or longer
40%
26%
21%
10.
11.
12. The next steps
• An international patent application has been filed
• A new company, Sartar Therapeutics Ltd., was founded to advance
the development of the new inhibitor
• Plans to develop a new formulation of the drug
• A Phase I/II clinical trial in the treatment of imatinib-refractory GIST is
being planned
13. What is SPARK?
• SPARK program founded in 2007 at Stanford university
• SPARK is a partnership between university and industry
-Purpose: to provide the education and mentorship to advance
research discoveries from the bench to the bedside
• Mentoring is provided by advisors with expertise in
-Product development
-Clinical care
-Business
Pasi Sorvisto, Helsinki Health Capital
14. How SPARK works
• Courses about the drug development process
• Funding: SPARK Scholars are funded for an average of 2 years
• Mentoring: Weekly seminars with industry and academic experts
• Advicing: Access to core facilities, assistance in creating partnerships
with industry
15. SPARK project selection criteria
• Product proposal reviews annually by experts
• The proposed therapy or diagnostic must:
• Address an unmet need
• Utilize a novel approach
• Have the potential to advance to clinic or commercialization with 2
years of funding
16. Example no: 2: Making a world-class tool to estimate GIST
patient outcome and the need for imatinib after surgery
1) All population-based GIST series were first identified from the literature1-9
Site Time period N
Western Sweden 1983-2000 231
Modena, Italy 1991-2004 157
Iceland 1990-2003 50
Northern Norway 1974-2003 457
Poland 2002-2009 582
Osaka, Japan 1987-2003 543
Southern Switzerland 1999-2005 78
Ancona, Italy 1987-2006 72
Czech/Slovak Republic 2001-2009 715
~2,500 patients
1Nilsson B et al. Cancer 2005;103:821-9, 2Mucciarini C et al. 2007;7:230, 3Tryggvason G et al. Dig Dis Sci 2007;52:2249-53, 4Steigen SE et al. APMIS
2007;115:289-98, 5Rutkowski P et al. Ann Surg Oncol 2007;14:2018-27, 6Takahashi T et al. Int J Clin Oncol 2007;12:369-74, 7Mazzola P et al. Histol
Histopathol 2008;23:1379-86, 8Braconi C et al. Ann Oncol 2008;19:706-10, 9Brabec P et al. Neoplasma 2009;56:459-64.
2) The best mathematics available (non-linear statistics) were applied to the
pooled world data (adj. prof. Aki Vehtari, Aalto University)
17. 100
90
80
70
60
50
40
30
20
10
0
0 1 2 3 4 5 6 7 8 9 10
Years since surgery
Survival 10-year risk of recurrence: 10%
3) A simple web-based platform for the user
19. Can we one day have a similar world top
university as Cambridge or Stanford in
Finland?
Of course!
We will need to create the positive cycle
• to secure good funding and resources
• this is likely to attract the best people
• …who will carry out top research